Scheme 1

The schematic illustration of BAF312@cRGD-CaP-NPs for tumor treatment through downregulating the S1PR1/P-STAT3/VEGFA axis. The BAF312@cRGD-CaP-NPs are gradually accumulated at the tumor sites in vivo via the EPR effect and active targeting mediated by cRGD and then uptaken by tumor cells and tumor blood vessel cells. Next, the nanoparticles release BAF312 in the acidic tumor microenvironment. Finally, BAF312@cRGD-CaP-NPs induce tumor cell apoptosis and destroy tumor blood vessel to maximize their antitumor efficacy through S1PR1/P-STAT3/VEGFA pathway